The cumulative incidence of hematologic malignant neoplasms leveled off at 2% by age 30 years in individuals with AR/XLR and 19% by age 70 years in individuals with AD–non-TINF2. Here, TINF2 is linked to hematopoietic and lymphoid cell neoplasm.